Implementation of amulticenter biobanking collaboration for next-generation sequencing-based biomarker discovery based on fresh frozen pretreatment tumor tissue biopsies

Sander Bins, Geert A. Cirkel, Christa G. Gadellaa-Van Hooijdonk, Fleur Weeber, Isaac J. Numan, Annette H. Bruggink, Paul J. van Diest, Stefan M. Willems, Wouter B. Veldhuis, Michel M. van den Heuvel, Rob J. de Knegt, Marco J. Koudijs, Erik van Werkhoven, Ron H.J. Mathijssen, Edwin Cuppen, Stefan Sleijfer, Jan H.M. Schellens, Emile E. Voest, Marlies H.G. Langenberg, Maja J.A. de JongeNeeltje Steeghs, Martijn P. Lolkema

Research output: Contribution to journalArticle

Abstract

Background. The discovery of novel biomarkers that predict treatment response in advanced cancer patients requires acquisition of high-quality tumor samples. As cancer evolves over time, tissue is ideally obtained before the start of each treatment. Preferably, samples are freshly frozen to allow analysis by next-generation DNA/RNA sequencing (NGS) but also for making other emerging systematic techniques such as proteomics and metabolomics possible. Here, we describe the first 469 image-guided biopsies collected in a large collaboration in The Netherlands (Center for Personalized Cancer Treatment) and show the utility of these specimens for NGS analysis. Patients and Methods. Image-guided tumor biopsies were performed in advanced cancer patients. Samples were fresh frozen, vital tumor cellularity was estimated, and DNA was isolated after macrodissection of tumor-rich areas. Safety of the image-guided biopsy procedures was assessed by reporting of serious adverse events within 14 days after the biopsy procedure. Results. Biopsy procedures were generally well tolerated.Major complications occurred in 2.1%, most frequently consisting of pain. In 7.3% of the percutaneous lung biopsies, pneumothorax requiring drainage occurred. The majority of samples (81%) contained a vital tumor percentage of at least 30%, from which at least 500 ng DNA could be isolated in 91%. Given our preset criteria, 74% of samples were of sufficient quality for biomarker discovery. The NGS results in this cohort were in line with those in other groups. Conclusion. Image-guided biopsy procedures for biomarker discovery to enable personalized cancer treatment are safe and feasible and yield a highly valuable biobank.

Original languageEnglish (US)
Pages (from-to)33-40
Number of pages8
JournalOncologist
Volume22
Issue number1
DOIs
StatePublished - Jan 1 2017

Keywords

  • Advanced cancer patients
  • Feasibility and safety
  • Image-guided biopsy procedures
  • Next-generation sequencing
  • Personalized cancer treatment
  • Precision oncology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Implementation of amulticenter biobanking collaboration for next-generation sequencing-based biomarker discovery based on fresh frozen pretreatment tumor tissue biopsies'. Together they form a unique fingerprint.

  • Cite this

    Bins, S., Cirkel, G. A., Gadellaa-Van Hooijdonk, C. G., Weeber, F., Numan, I. J., Bruggink, A. H., van Diest, P. J., Willems, S. M., Veldhuis, W. B., van den Heuvel, M. M., de Knegt, R. J., Koudijs, M. J., van Werkhoven, E., Mathijssen, R. H. J., Cuppen, E., Sleijfer, S., Schellens, J. H. M., Voest, E. E., Langenberg, M. H. G., ... Lolkema, M. P. (2017). Implementation of amulticenter biobanking collaboration for next-generation sequencing-based biomarker discovery based on fresh frozen pretreatment tumor tissue biopsies. Oncologist, 22(1), 33-40. https://doi.org/10.1634/theoncologist.2016-0085